Novavax Inc vs Teucrium Soybean Fund — how do they compare? Novavax Inc trades at $7.93 (market cap $1.31B), while Teucrium Soybean Fund trades at $24.82. The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SOYB | |
|---|---|---|
Market Cap | $1.31B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $11.19 | $26.28 |
52-Week Low | $6.22 | $21.46 |
Enterprise Value | $889.30M | — |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
No Aura AI signal available yet.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →